Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Glycorex Transplantation AB (NGM:GTAB B) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Glycorex Transplantation AB Quick Ratio Related Terms
Glycorex Transplantation AB Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:GTAB B vs VRTX, REGN, RVMD: Quick Ratio Comparison
For the Biotechnology subindustry, Glycorex Transplantation AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glycorex Transplantation AB Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Glycorex Transplantation AB's Quick Ratio falls into.
Glycorex Transplantation AB Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glycorex Transplantation AB (NGM:GTAB B) has a Quick Ratio of 1.16 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Glycorex Transplantation AB and its competitors. This is 28% below median its historical median of 1.60. Over the past decade, Glycorex Transplantation AB's Quick Ratio has ranged from 0.97 to 5.21. According to the industry distribution chart, Glycorex Transplantation AB ranks #1096 out of 1412 companies in the Biotechnology industry, placing it in the top 77.6%.
Is Glycorex Transplantation AB's Quick Ratio too high?
Glycorex Transplantation AB's current Quick Ratio of 1.16 is 28% below median its 10-year median of 1.60. Over the past 10 years, this metric has ranged from a low of 0.97 to a high of 5.21. The Biotechnology industry median Quick Ratio is 3.57. Glycorex Transplantation AB's value of 1.16 is 67.5% below this industry median. Based on the distribution chart, Glycorex Transplantation AB ranks #1096 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Glycorex Transplantation AB has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Glycorex Transplantation AB ranks #1096 out of 1412 companies for Quick Ratio. This places Glycorex Transplantation AB in the lower half of its industry. The industry median Quick Ratio is 3.57. Glycorex Transplantation AB's value of 1.16 is 67.5% below this benchmark. Historically, Glycorex Transplantation AB's own Quick Ratio has ranged from 0.97 to 5.21 over the past decade. While the company's 10-year median is 1.60 vs. the industry median of 3.57, Glycorex Transplantation AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.57, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glycorex Transplantation AB's current Quick Ratio of 1.16 is 67.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Glycorex Transplantation AB and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glycorex Transplantation AB's current Quick Ratio is 1.16, which is 28% below median its own 10-year median of 1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (NGM:GTAB B) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.81, compared to a current price of kr1.46 — trading 19.3% below its estimated fair value. The current Quick Ratio is 1.16, which is 28% below median its 10-year median of 1.60 and 67.5% below the Biotechnology industry median of 3.57. Glycorex Transplantation AB's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Glycorex Transplantation AB (NGM:GTAB B), the current Quick Ratio is 1.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glycorex Transplantation AB (NGM:GTAB B) Overvalued in 2026?
Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued.
The current stock price of kr1.46 is trading 19.3% below its estimated GF Value™ of kr1.81.
GuruFocus considers Glycorex Transplantation AB to be Modestly Undervalued.
Key valuation signals for NGM:GTAB B:
Quick Ratio: 1.16 (28% below median its 10-year median of 1.60)
GF Value™: kr1.81 vs. price of kr1.46 (19.3% below fair value)
Industry Position: 67.5% below the Biotechnology median (#1096 of 1412)
No single metric tells the full story. See the NGM:GTAB B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
61GF Score
Get the complete analysis for NGM:GTAB B
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:GTAB B has been successfully added to your 
